FierceBiotech 2026年3月9日 Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
FierceBiotech 2026年3月9日 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech 2026年3月9日 Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
FierceBiotech 2026年3月9日 Why early developability assessment is a strategic necessity in modern antibody discovery
FierceBiotech 2026年3月6日 FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
FierceBiotech 2026年3月6日 Beam rejigs deal to retain base editing technology amid partner's dissolution
FierceBiotech 2026年3月6日 Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
FierceBiotech 2026年3月6日 Senior FDA official refutes uniQure's claims amid controversy over Huntington's gene therapy
FierceBiotech 2026年3月6日 Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
FierceBiotech 2026年3月6日 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug